New melanoma cancer drug in development shows promise

University of Oxford and Immunocore Ltd have investigated Tebentafusp, a new anti-tumor immune response drug for patients with metastatic melanoma

The relationship between iRhom2 and KRAS proteins

Development Fund winners from the Freeman group are investigating newly discovered proteins and their potential as targets for new cancer treatments

The impact of COVID-19 on cancer patients

A new study from the UK Coronavirus Cancer Monitoring Project (UKCCMP) has investigated which cancer patients may be more susceptible to the impacts of coronavirus

IL-22 pathway linked to poor prognosis in colon cancer

Research shows how IL-22 interacts with KRAS mutant tumours to promote excessive growth in colorectal cancer

Oxford lymphoid study group established

The new Oxford Lymphoid Disorder Study Group, chaired by Dr Graham Collins, will be launched this September in Blood Cancer Awareness Month

The relationship between unexpected weight loss & cancer

New research will help GPs to identify the signs they should look for to swiftly diagnose cancer in people with unexpected weight loss

TP53 gene determines severe blood cancer development

A new study has found that the allelic appearance of the TP53 gene has great impact on development of severe types of blood cancer

Using DNA & RNA to treat cancers

Cancer research UK Oxford Centre Development Fund Awardees Ysobel Baker and Tom Brown investigate the potential of DNA and RNA molecules as precision cancer treatments